@nytimes
The New York Times
5 days ago
In a powerful statement of disagreement with the FDA’s approval of Biogen’s controversial Alzheimer’s drug, three scientists have resigned from the independent committee that advised the agency on the treatment. https://t.co/Y7J2YmKkZN
36
153
349

Replies

@BeingAmore
Being Amore
5 days ago
1
0
0
@jacob_mauren
Jacob Mauren
5 days ago
@nytimes So the company is charging 56k to scam people. Nice.
1
1
5
@sameer_bhardwaj
Sameer Bhardwaj
5 days ago
0
0
0
@runoutloud
Ashlee Mayfield
5 days ago
0
0
0
@booksnips
Susan C-P
5 days ago
@nytimes “This might be the worst approval decision that the F.D.A. has made that I can remember,” said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School and Brigham and Women’s Hospital. Serious side effects, ppl, and no data suggesting it works as claimed.
2
1
13
@ruchira_s924
Ruchira
5 days ago
@nytimes Strange, FDA .. is still sitting on approval of mRNA vaccines but has no problem approving a controversial drug??
0
0
5
@vanreuter
George Brenner
5 days ago
@nytimes It’s profit over science, typical
0
1
8
@buddaprotocol
Megachurch Pastor
5 days ago
@nytimes Follow the money 💴
0
0
1
@bayside60
dr. kaye
5 days ago
0
0
1